ACHIEVING ~80% TUMOUR CONTROL IN PRECLINICAL STUDIES

This is very significant

Announcement 4th March 2024

INV043 DRAMATICALLY IMPROVED IMMUNE CHECKPOINT INHIBITOR EFFECTIVENESS WHEN USED IN COMBINATION, ACHIEVING ~80% TUMOUR CONTROL IN PRECLINICAL STUDIESHighlights:

 Topically applied INV043 in combination with an immune checkpoint inhibitor (ICI) resulted in ~80% of subjects being tumour-free. The study was conducted by Peter Mac using immune competent anal squamous cell carcinoma (ASCC) in vivo models

 ICIs, the standard of care for the treatment of several cancers, are a class of immunotherapy drug. Despite widespread clinical use as a monotherapy, ICI effectiveness is typically limited to a small proportion of patients

 Results support previous findings by Hudson Institute using intratumorally administered INV043 in combination with ICIs on another cancer type (triple negative breast cancer)

 Opens additional treatment options for upcoming clinical trial programs that span multiple cancers  ASCC has potential to be designated as an orphan indication – leading to an expedited regulatory approval process

 The findings reinforce the potential for collaboration partnerships using combination therapies to extend the patent life of blockbuster ICIs

 Global ICI market forecast to grow at 16.8% CAGR to reach US$189 billion by 20321